RGNX · REGENXBIO Inc.
$11.06
-0.96 (-7.99%)
At close · Aug 20
Market Cap
$753.87M
Shares
66.01M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$11.06
Open$11.98
Day$11.03–12.08
52W close$5.65–15.98
Avg vol 30d1.5M
Short int7.2M · 10.9% float · 3.8d
Short vol60%
Last earningsAug 6, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 2, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Strong Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
Golden cross
Price vs 200-day avg
+6%
above
Price vs 50-day avg
+4%
above
RSI (14)
52
neutral
MACD trend
Positive
52-week position
52%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+8%
trailing
6-month return
+22%
trailing
YTD return
−23%
this year
Relative strength
+11%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Golden cross
50d $11 › 200d $10 — 50d above 200d
Institutional flow
Distributing
-8% holders QoQ · +26 funds added
Insider flow
Distributing
Net -$688.8K over 90 days · 100% sells
Short interest
Falling
10.90% of float · ▼ -16.6% MoM · 3.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
166 holders — mid 3-yr range
Squeeze score
69
elevated · 0–100
Fundamentals
Revenue growth
+126%
Y/Y
EPS growth
+18%
Y/Y
Free cash flow
$-126.4M
Balance sheet
$34.5M
net cash
Quant / Vol
risk profile
Volatility
90%
annualized · 1-yr
Max drawdown
−65%
past year
ATR
7.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
Golden cross
Bullish
Price vs 200-day avg
+6%
Bullish
Price vs 50-day avg
+4%
Bullish
RSI (14)
52
Neutral
MACD trend
Positive
Bullish
52-week position
52%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
Golden cross
50d $11 › 200d $10 — 50d above 200d
Institutional flow
Distributing
-8% holders QoQ · +26 funds added
Insider flow
Distributing
Net -$688.8K over 90 days · 100% sells
Short interest
Falling
10.90% of float · ▼ -16.6% MoM · 3.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
166 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $6
Now $11 · 52%
Range high $16
vs 200-day avg +6%
vs 50-day avg +4%
50-day above 200-day golden cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RGNX
this stock
REGENXBIO Inc.
|
$753.87M | -23.2% | +126.5% | — | 10.9% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RGNX | +3.8% | +7.9% | +22.4% | +14.1% | -23.2% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +5.7% | +4.6% | +11.2% | +12.1% | -35.0% |
Key facts
CIK
1590877
CUSIP
75901B107
13F (30d)
154 filings
154 filers
Visit website
Investor relations